期刊
HUMAN MOLECULAR GENETICS
卷 20, 期 -, 页码 R69-R78出版社
OXFORD UNIV PRESS
DOI: 10.1093/hmg/ddr105
关键词
-
资金
- UK Medical Research Center
- Muscular Dystrophy Campaign
- Muscular Dystrophy Association USA
- Association Monegasque contre les myopathies
- Duchenne Parent project France
- NIH [R37AR40864]
- American Australian Association
- Medical Research Council [G0801763] Funding Source: researchfish
- MRC [G0801763] Funding Source: UKRI
Muscular dystrophies are a heterogeneous group of genetic disorders characterized by muscle weakness and wasting. Duchenne muscular dystrophy (DMD) is the most common and severe form of muscular dystrophy, and although the molecular mechanisms of the disease have been extensively investigated since the discovery of the gene in 1986, there is currently no effective treatment. However, new gene-based therapies have recently emerged with particular noted advances in using conventional gene replacement strategies, RNA-based technology and pharmacological approaches. While the proof of principle has been demonstrated in animal models, several clinical trials have recently been undertaken to investigate the feasibility of these strategies in patients. In particular, antisense-mediated exon skipping has shown encouraging results and holds promise for the treatment of dystrophic muscle. Here, we summarize the recent progress in therapeutic approaches to muscular dystrophies, with an emphasis on gene therapy and exon skipping for DMD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据